entertainment -WSS

entertainment

author：Wikipedia 2025-09-10 08:41:07 - browse：75

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Health tech investors get more selective as pandemic boom fades

WSS

Address the ethical violations that led to 'Three Identical Strangers'

Paxlovid should be available without a positive Covid test

Intercept Pharmaceuticals sells itself for less than $1 billion

Covid vaccines: Private market messier than government rollout

Mindstrong's demise and the future of mental health care

WHO recommends dropping component of many flu vaccines

explore

entertainment

Wikipedia

Heart attack and stroke risk calculators need revising

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Jerome Adams on the need for new antivirals for Covid

Roivant's CEO is a star, but biotech's black hole persists

In Memoriam: Notable people who died in 2023

Did you have Obamacare on your GOP debate bingo card?

Bright Health sells Medicare Advantage business to Molina

Paxlovid should be available without a positive Covid test

Psychedelics group wrestles with new pharma identity

Merck, Daiichi strike cancer drug pact worth up to $22 billion

knowledge

STAT Readout Newsletter: Biotech news today

Researchers use wearables data and AI to predict preterm birth risk

Biogen shutters digital health group, ends Apple study, in cost cutting move

STAT Readout Newsletter: Biotech news today

Address the ethical violations that led to 'Three Identical Strangers'

Readout LOUD podcast: Live from the 2023 STAT Summit

hotspot

hotspot

leisure time

Wikipedia